ABOUT NEUROLOGIX
Neurologix, Inc. (NRGX.OB) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and Central Nervous System (CNS). Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. Current company programs address such conditions as Parkinson's disease, epilepsy, depression and Huntington's disease, all of which are large markets not adequately served by current therapeutic options.
Neurologix's business is characterized by:
- A novel gene transfer approach to therapy that results in the targeted expression of sustained pharmacological effects within the brain.
- Phase 2 clinical trial results for advanced Parkinson's disease (PD) wherein study participants experienced statistically significant and clinically meaningful improvements in off-medication motor scores compared to patients receiving sham surgery. In this double-blinded trial, benefit was seen at one month and continued virtually unchanged throughout the six month blinded study period. The results also demonstrated a positive safety profile for NLX-P101, with no serious adverse events related to the gene therapy or surgical procedure reported.
- An experienced management team and cost-efficient business structure, actively assisted by scientific advisors and clinical investigators who are world recognized thought leaders and founding scientists in the field of gene therapy for CNS diseases.
“… clinical outcomes [from the Phase 1 Parkinson’s disease study] were encouraging. Substantial improvements in both the off and on states were evident, beginning at three months after surgery and continuing until the end of the trial.”
The Lancet, June 23, 2007